Case Analysis: Systemic Validation Failures and Contamination Risks in Sterile Compounding (FDA Form 483 Review)
[中譯] 案例分析：無菌製劑製造系統性確效失效與污染風險（FDA Form 483 Review）

1. Strategic Context and Executive Overview
[中譯] 1. 策略背景與高階概述

The FDA’s inspection of F.H. Investments, Inc. (dba Asteria Health) provides a critical case study on the catastrophic consequences of decoupling engineering controls from regulatory strategy.
[中譯] 美國 FDA 對於 F.H. Investments, Inc.（商號：Asteria Health）的檢查，提供了一個關於將工程控制與法規策略脫鉤所導致之災難性後果的關鍵案例研究。

For Section 503B outsourcing facilities, a "state of control" is not a bureaucratic checkbox; it is an engineering reality defined by the physical integrity of the manufacturing environment.
[中譯] 對於 Section 503B 外包設施而言，「受控狀態」並不是一個官僚主義的勾選方塊；它是一個由製造環境實體完整性所定義的工程現實。

This inspection demonstrates how the failure to execute facility-specific Performance Qualifications (PQ) and Process Performance Qualifications (PPQ) results in more than just administrative citations—it leads to systemic data integrity breaches and the physical contamination of implantable drug products.
[中譯] 本次檢查表明，未能執行特定設施的效能確認（PQ）和製程效能確認（PPQ）不僅會導致行政裁罰，還會導致系統性的數據完整性缺失以及植入性藥物產品的實體污染。

Detail [中譯] 項目	Information [中譯] 內容
Firm Name [中譯] 公司名稱	F.H. Investments, Inc. (dba Asteria Health) [中譯] F.H. Investments, Inc.（商號：Asteria Health）
Facility Type [中譯] 設施類型	Outsourcing Facility (503B) [中譯] 外包設施 (503B)
Inspection Dates [中譯] 檢查日期	12/05/2025–12/19/2025 [中譯] 2025年12月5日至2025年12月19日
Primary Product Focus [中譯] 主要產品核心	Implantable hormone pellets (Testosterone, Estradiol, and complex combinations like Testosterone/Anastrozole) [中譯] 植入性荷爾蒙錠劑（睪固酮、雌二醇，以及如睪固酮/阿那曲唑等複雜組合）

These administrative facts frame a facility operating at significant volume across multiple states, yet the technical findings uncover a profound absence of the GxP engineering foundations required to maintain pharmaceutical quality and patient safety.
[中譯] 這些行政事實描繪出一家在多個州以相當大產量營運的設施，然而技術調查結果卻揭露其嚴重缺乏維持藥品品質和病人安全所需的 GxP 工程基礎。

2. Analysis of Regulatory Observations and Legal Basis
[中譯] 2. 法規觀察項與法律依據分析

In the regulatory landscape, the "State of Control" represents the convergence of validated processes and robust quality oversight.
[中譯] 在法規環境中，「受控狀態」代表了經確效的製程與穩健品質監督的結合。

As documented in this 483, Asteria Health’s operations lacked this fundamental baseline, triggering severe implications under the Federal Food, Drug, and Cosmetic Act.
[中譯] 如本 483 表單所述，Asteria Health 的營運缺乏此一基本基準，從而觸發了《聯邦食品、藥品和化妝品法案》下的嚴重後果。

When a firm fails to validate its processes, the resulting products are legally "adulterated," as the lack of engineering certainty regarding their "identity, strength, purity, and quality" renders them potentially injurious to health.
[中譯] 當一家公司未能確效其製程時，產出的產品在法律上即被視為「劣藥（Adulterated）」，因為對其「身分、強度、純度和品質」缺乏工程上的確定性，使其可能對健康造成危害。

Pillar 1: Process and Equipment Qualification Gaps (Observations 1, 2, 6)
[中譯] 第一支柱：製程與設備確認差距（觀察項 1、2、6）

The firm’s failure to establish adequate production controls (Observation 1) stems from a total lack of facility-specific PQ and PPQ.
[中譯] 該公司未能建立適當的生產管制（觀察項 1），源於完全缺乏特定設施的 PQ 和 PPQ。

Asteria Health moved pellet presses between rooms without requalification, erroneously claiming no impact on the "validated state."
[中譯] Asteria Health 在未進行重新確認的情況下在房間之間移動錠劑壓片機，錯誤地聲稱對「確效狀態」沒有影響。

They were unaware that vacuum pressure gauges—critical for adequate product flow and the shaping of pellets—required calibration (Observation 1b).
[中譯] 他們不知道真空壓力錶（對適當的物料流動和錠劑成型至關重要）需要進行校正（觀察項 1b）。

This technical oversight directly contributed to process failures where pellets "would not hold together" (DV25-042).
[中譯] 這一技術疏忽直接導致了製程失敗，即錠劑「無法維持形狀而碎裂」（DV25-042）。

Furthermore, the firm relied on non-representative dose audits for sterilization, ignoring variables such as pellet density, size, and facility-specific bioburden that fluctuate between different manufacturing environments.
[中譯] 此外，該公司依賴非代表性的滅菌劑量稽核，忽視了在不同製造環境之間波動的錠劑密度、尺寸和特定設施微生物負載等變數。

Pillar 2: Contamination Control and Facility Integrity (Observations 5, 10)
[中譯] 第二支柱：污染控制與設施完整性（觀察項 5、10）

Physical contamination was a recurring, systemic issue characterized by mechanical impingement and frictional wear at the pellet-die interface.
[中譯] 實體污染是一個反覆出現的系統性問題，其特徵是錠劑與模具介面處的機械干涉和摩擦磨損。

Inspectors documented ongoing metallic and translucent shavings in products such as Testosterone 87.5mg and Estradiol 15mg pellets (Observation A).
[中譯] 檢查員記錄了在 Testosterone 87.5mg 和 Estradiol 15mg 錠劑等產品中持續產生的金聯與透明碎屑（觀察項 A）。

The firm’s "loop of failure" was complete: they implemented metal detectors as a CAPA in October 2025 but failed to document test results or investigate rejects, instead treating fragments as "waste."
[中譯] 該公司的「失敗迴路」已然形成：他們於 2025 年 10 月導入金屬檢查機作為 CAPA，但未能記錄測試結果或調查剔除品，而是將碎片視為「廢棄物」。

This was exacerbated by a cracked containment shield on a pellet press used for highly potent hormones, which created a non-smooth surface that was impossible to decontaminate or clean (Observation 5).
[中譯] 專用於高活性荷爾蒙的錠劑壓片機上破裂的隔離防護罩加劇了這一狀況，這造成了一個無法進行去污或清潔的非光滑表面（觀察項 5）。

Pillar 3: Quality Unit Oversight and Data Integrity (Observations 3, 4, 7, 8, 9)
[中譯] 第三支柱：品質部門監督與數據完整性（觀察項 3、4、7、8、9）

The Quality Unit (QU) demonstrated a pervasive lack of authority, evidenced by the release of Lot 254000107 despite known errors in the master batch record (Observation 3A).
[中譯] 品質部門（QU）表現出普遍缺乏權限，這可由明知主批次記錄存在錯誤卻仍放行 Lot 254000107 得到證實（觀察項 3A）。

Data integrity was fundamentally compromised; sequence reports reveal that all potency testing performed for batch release since May 2025 was executed under "Admin" profiles with unrestricted access to delete sequences and alter audit trails (Observation 9A).
[中譯] 數據完整性受到根本性的破壞；序列報告顯示，自 2025 年 5 月以來執行的所有用於批次放行的含量與效價測試，皆是在具有無限制刪除序列和更改稽核追蹤權限的「Admin」帳號下執行的（觀察項 9A）。

Additionally, the firm assigned 365-day expiration dates without facility-specific stability data, ignoring the fact that environmental variables—including unique microbial flora, HVAC performance, and facility layout—render "legacy data" from other sites technically invalid.
[中譯] 批次數據外推無效：該公司在缺乏特定設施穩定性數據的情況下指定了 365 天的有效期限，忽視了環境變數（包括獨特的微生物相、HVAC 效能和設施佈局）會使來自其他廠區的「歷史數據」在技術上失效的事實。

Observation 1: "Your firm failed to establish adequate written procedures for production and process controls... Your firm has not performed Performance Qualification (PQ) on any equipment... nor has your firm executed Process Validation Qualification (PPQ)... Your justification includes legacy data from commercial batches... However, your firm has made changes to your manufacturing process by, for example: Adding new equipment (i.e., metal detectors, weight sorters)... and changing drug formulation in the master batch record... for Testosterone/Anastrozole pellet products." These procedural failures manifest as physical risks, where the lack of engineering discipline creates a direct conduit for contaminated and improperly dosed medicine to reach the patient.
[中譯] 觀察項 1：「貴公司未能為生產和製程管制建立適當的書面程序……貴公司未對任何設備執行效能確認（PQ）……貴公司亦未執行製程驗證確認（PPQ）……貴公司的理由包括來自商業批次的歷史數據……然而，貴公司已對製造製程進行了變更，例如：增加新設備（即金屬檢查機、重量分選機）……以及更改 Testosterone/Anastrozole 錠劑產品的主批次記錄……」這些程序上的失敗表現為實體風險，其中缺乏工程紀律為受污染和劑量錯誤的藥品到達病人手中創造了一條直接通道。

3. The "So What?" Layer: Risk Analysis from Persimmon Engineering
[中譯] 3. 「那又怎樣？」層面：梁山工程顧問有限公司的風險分析

From our perspective at Persimmon Engineering, the Asteria Health case highlights how a "check-the-box" approach to compliance creates catastrophic business and safety risks.
[中譯] 從我們梁山工程顧問有限公司(Persimmon Engineering)的角度來看，Asteria Health 案例突顯出「勾選方塊式」的合規方法如何製造災難性的業務與安全風險。

When engineering failures are treated as "opportunities for improvement" rather than critical deviations, the facility loses its ability to protect the patient.
[中譯] 當工程失敗被視為「改進機會」而非關鍵偏差時，設施便失去了保護病人的能力。

Patient Safety Risk (Dose Dumping): The absence of dissolution and hardness testing (Observation 6) is a critical failure for a controlled-release implantable. Without these tests, there is no verification that the pellet maintains structural integrity over months. This creates a high risk of "dose dumping," where the patient receives a toxic release of hormones immediately upon implantation.
[中譯] 病人安全風險（劑量傾卸 Dose Dumping）：對於控釋植入性產品而言，缺乏溶離度和硬度測試（觀察項 6）是一個關鍵性的失敗。缺乏這些測試，便無法驗證錠劑在數月內能否維持結構完整性。這製造了極高的「劑量傾卸」風險，使病人在植入後立即接受到毒性劑量的荷爾蒙釋放。

Physical Injury Risk (Foreign Matter): The ongoing generation of metallic shavings (mechanical wear) and translucent shavings (plastic/gasket degradation) in implantable products poses severe risks of embolism and localized inflammation. Treating these as "waste" rather than evidence of equipment failure demonstrates a dangerous lack of engineering oversight.
[中譯] 實體傷害風險（異物碎屑）：植入性產品中持續產生的金屬碎屑（機械磨損）和透明碎屑（塑料/墊圈降解），帶來了嚴重的栓塞和局部發炎風險。將其視為「廢棄物」而非設備失效的證據，表明了工程監督的危險缺失。

Legal and Operational Risk: The firm ignored third-party audit warnings from September 2025 and left critical CAPAs (for stability and validation) open for over eight months. Combined with the systemic use of "Admin" credentials for testing, the firm has effectively abandoned its "State of Control," making a Warning Letter or Consent Decree almost certain. Identifying these risks is the first step toward a robust, engineering-led remediation strategy that restores the facility’s viability.
[中譯] 法律與營運風險：該公司忽視了 2025 年 9 月的第三方稽查警告，並將關鍵的 CAPA（針對穩定性和確效）維持開啟狀態超過八個月。結合在檢驗中系統性使用「Admin」憑證的做法，該公司實際上已放棄了其「受控狀態」，使警告信（Warning Letter）或同意令（Consent Decree）幾乎成為必然。識別 these 風險是邁向穩健、工程導向的整治策略的第一步，從而恢復設施的生存能力。

4. Persimmon Engineering’s Roadmap to Remediation
[中譯] 4. 梁山工程顧問有限公司的整治藍圖

Remediation must be holistic, addressing the mechanical root causes while rebuilding the Quality Management System (QMS) from the ground up.
[中譯] 整治必須是全方位的，在從頭重建品質管理系統（QMS）的同時，解決機械方面的根本原因。

Stage 1: Mechanical & Facility Remediation
[中譯] 第一階段：機械與設施整治

The firm must immediately replace the cracked containment shields to ensure aseptic surfaces are smooth and cleanable. A rigorous "wear and tear" audit must be performed on all microcapper wheels and pellet press sieving processes. This audit must identify the specific mechanical interfaces causing "mechanical impingement" and replace all worn components with GxP-compliant parts designed to withstand the frictional stresses of pellet production.
[中譯] 該公司必須立即更換破裂的隔離防護罩，以確保無菌表面光滑且易於清潔。必須對所有微型封蓋輪和錠劑壓片機篩分製程執行嚴格的「磨損與耗損」稽核。該稽核必須識別導致「機械干涉」的特定機械接觸面，並用旨在承受錠劑生產摩擦應力的 GxP 合規零件汰換所有磨損組件。

Stage 2: Validation & Qualification (V&Q) Overhaul
[中譯] 第二階段：確效與確認（V&Q）大修

We mandate a full IQ/OQ/PQ cycle for all production equipment. The use of "empty vials" for qualification is strictly forbidden; PQ must be executed using representative drug products (including the most complex combinations) to simulate actual manufacturing stresses as required by Observation 4c. This must include the calibration of all critical process parameters, specifically the vacuum pressure gauges essential for pellet shaping.
[中譯] 我們強制要求對所有生產設備執行完整的 IQ/OQ/PQ 週期。嚴格禁止使用「空瓶」進行確認；如觀察項 4c 所要求，PQ 必須使用具代表性的藥物產品（包括最複雜的組合）來執行，以模擬實際的製造應力。這必須包括所有關鍵製程參數的校正，特別是對於錠劑成型至關重要的真空壓力錶。

Stage 3: QMS & Data Integrity Fortification
[中譯] 第三階段：QMS 與數據完整性強化

The firm must implement a restricted-access HPLC system where the "Admin" profile is reserved for non-routine IT personnel only. A formal Defect Library must be established for visual inspections, specifically differentiating between metallic (equipment wear) and translucent (gasket/seal wear) shavings to allow for accurate root cause analysis. CAPA management must be restructured to prioritize fundamental cGMP deficiencies over "process gaps," with the Quality Unit empowered to halt production for any OOS result.
[中譯] 該公司必須實施一個權限受限的 HPLC 系統，其中「Admin」權限僅保留給非例行性的 IT 人員。必須建立一個用於目視檢查的正式缺陷庫，特別是區分金屬碎屑（設備磨損）和透明碎屑（墊圈/密封件磨損），以便進行準確的根本原因分析。CAPA 管理必須進行重組，將根本性的 cGMP 缺陷置於「製程差距」之上，並賦予品質部門在出現任何 OOS（規格外）結果時中止生產的權限。

Immediate Actions [中譯] 即刻行動	Long-term Strategic Shifts [中譯] 長期策略轉變
Replace cracked shields and worn microcapper wheels/sieves. [中譯] 更換破裂的防護罩及磨損的微型封蓋輪/篩網。	Transition from "legacy data" to site-specific validation. [中譯] 從依賴「歷史數據」轉向特定廠區的確效。
Revoke routine "Admin" access and audit all potency testing since May 2025. [中譯] 取消常規的「Admin」存取權限，並審計自2025年5月以來的所有含量與效價測試。	Implement a culture of engineering-led root cause analysis. [中譯] 建立以工程為導向的根本原因分析文化。
Document and investigate all metal detector rejects. [中譯] 記錄並調查所有金屬檢查機的剔除品。	Establish a robust, site-specific stability and expiry program. [中譯] 建立穩健、特定廠區的穩定性與有效期限計畫。
Implement hardness and dissolution testing for every batch. [中譯] 對每一批次實施硬度和溶離度測試。	Align maintenance schedules with actual mechanical wear rates. [中譯] 使維護排程與實際的機械磨損率相結合。

We invite you to leverage Persimmon Engineering’s expertise to navigate these complexities and avoid the documented pitfalls found in the Asteria Health case.
[中譯] 我們邀請您利用梁山工程顧問有限公司(Persimmon Engineering)的專業知識來應對這些複雜性，並避免 Asteria Health 案例中所記錄的陷阱。

5. Conclusion and Professional Synthesis
[中譯] 5. 結論與專業綜合審查

The failures at Asteria Health represent a simultaneous collapse of engineering foresight and quality culture. By relying on inappropriate "legacy data" and ignoring the physical signs of mechanical wear, the firm produced "adulterated" products that placed patients at extreme risk. Regulatory compliance is not a static milestone; it is a continuous state of engineering and operational discipline. Persimmon Engineering specializes in transforming 483-level vulnerabilities into gold-standard manufacturing processes. We bridge the gap between mechanical performance and regulatory expectations, ensuring that your facility operates with the technical precision required for patient safety and business continuity. Contact us today to secure your facility's future.
[中譯] Asteria Health 的失敗代表了工程遠見與品質文化的同時崩潰。通過依賴不恰當的「歷史數據」並忽視機械磨損的實體跡象，該公司生產了使患者面臨極大風險的「劣藥」。法規合規並不是一個靜態的里程碑；它是一個連續的工程與營運紀律狀態。梁山工程顧問有限公司(Persimmon Engineering)專門將 483 級別的漏洞轉化為黃金標準的製造製程。我們彌合了機械性能與法規期望之間的差距，確保您的設施在病人安全和業務連續性所需的技術精準度下營運。歡迎立即與我們聯絡，以保障您設施的未來。